2026-10-01T23:23:46Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/121992026-09-30T00:05:47Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210

Labrador, Jorge Saiz Rodríguez, Miriam de Miguel, Dunia de Laiglesia, Almudena Rodríguez Medina, Carlos Vidriales, María Belén Pérez Encinas, Manuel Sánchez Sánchez, María José Cuello, Rebeca Roldán Pérez, Alicia Vives, Susana Benzo Callejo, Gonzalo Colorado, Mercedes García Fortes, María Sayas, María José Olivier, Carmen Recio, Isabel Conde Royo, Diego Bienert García, Álvaro Vahi, María Muñoz García, Carmen Seri Merino, Cristina Tormo, Mar Vall llovera, Ferran Foncillas, María Ángeles Martínez Cuadrón, David Sanz, Miguel Ángel Montesinos, Pau 2026-09-29T09:40:16Z 2026-09-29T09:40:16Z 2022-03 https://hdl.handle.net/10259/12199 10.3390/CANCERS14071734 2072-6694 The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the effectiveness of VEN in a cohort of 51 RR-AML patients and evaluated for predictors of response and overall survival (OS). The median age was 68 years, most were at high risk, 61% received ≥2 therapies for AML, 49% had received hypomethylating agents, and ECOG was ≥2 in 52%. Complete remission (CR) rate, including CR with incomplete hematological recovery (CRi), was 12.4%. Additionally, 10.4% experienced partial response (PR). The CR/CRi was higher in combination with azacitidine (AZA; 17.9%) than with decitabine (DEC; 6.7%) and low-dose cytarabine (LDAC; 0%). Mutated NPM1 was associated with increased CR/CRi. Median OS was 104 days (95% CI: 56–151). For the combination with AZA, DEC, and LDAC, median OS was 120 days, 104 days, and 69 days, respectively; p = 0.875. Treatment response and ECOG 0 influenced OS in a multivariate model. A total of 28% of patients required interruption of VEN because of toxicity. Our real-life series describes a marginal probability of CR/CRi and poor OS after VEN-based salvage. Patients included had very poor-risk features and were heavily pretreated. The small percentage of responders did not reach the median OS M.S.-R. research was supported by Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation, through the Sara Borrell Program (CD21/00022). application/pdf eng MDPI Cancers. 2022, V. 14, n. 7, art. 1734 https://doi.org/10.3390/ cancers14071734 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Venetoclax Acute myeloid leukemia Relapsed Refractory Leucemia mieloide aguda Acute myeloid leukemia Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Cancers 14 7 1734